Doxorubicin and Paclitaxel versus Fluorouracil, Doxorubicin and Cyclophosphamide as First-Line Therapy for Women with Advanced Breast Cancer: Long-Term Analysis of the Previously Published Trial

Background: The aim of this study was to perform an independent review of the efficacy data and to determine whether the efficacy difference observed in a phase III randomised clinical trial that compared doxorubicin plus paclitaxel (AT) versus fluorouracil/doxorubicin/cyclophosphamide (FAC) in firs...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncology research and treatment 2009-09, Vol.32 (8-9), p.468-472
Hauptverfasser:	Jassem, Jacek, Pienkowski, Tadeusz, Pluzanska, Anna, Jelic, Svetislav, Gorbunova, Vera, Berzins, Juris, Nagykalnai, Thomas, Biganzoli, Laura, Aloe, Alessandra, Astier, Ludovic, Munier, Stephane
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast Neoplasms - drug therapy Breast Neoplasms - mortality Breast Neoplasms - secondary Cyclophosphamide - therapeutic use Doxorubicin - therapeutic use Europe - epidemiology Female Fluorouracil - therapeutic use Humans Middle Aged Original Article · Originalarbeit Paclitaxel - therapeutic use Prevalence Survival Analysis Survival Rate Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!